Activation pathway of a G protein-coupled receptor uncovers conformational intermediates as targets for allosteric drug design.

G蛋白偶联受体的激活途径揭示了构象中间体,可作为变构药物设计的靶点

阅读:3
作者:Lu Shaoyong, He Xinheng, Yang Zhao, Chai Zongtao, Zhou Shuhua, Wang Junyan, Rehman Ashfaq Ur, Ni Duan, Pu Jun, Sun Jinpeng, Zhang Jian
G protein-coupled receptors (GPCRs) are the most common proteins targeted by approved drugs. A complete mechanistic elucidation of large-scale conformational transitions underlying the activation mechanisms of GPCRs is of critical importance for therapeutic drug development. Here, we apply a combined computational and experimental framework integrating extensive molecular dynamics simulations, Markov state models, site-directed mutagenesis, and conformational biosensors to investigate the conformational landscape of the angiotensin II (AngII) type 1 receptor (AT(1) receptor) - a prototypical class A GPCR-activation. Our findings suggest a synergistic transition mechanism for AT(1) receptor activation. A key intermediate state is identified in the activation pathway, which possesses a cryptic binding site within the intracellular region of the receptor. Mutation of this cryptic site prevents activation of the downstream G protein signaling and β-arrestin-mediated pathways by the endogenous AngII octapeptide agonist, suggesting an allosteric regulatory mechanism. Together, these findings provide a deeper understanding of AT(1) receptor activation at an atomic level and suggest avenues for the design of allosteric AT(1) receptor modulators with a broad range of applications in GPCR biology, biophysics, and medicinal chemistry.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。